Julie Forman-Kay

Julie Forman-Kay is Program Head and Senior Scientist in the Molecular Medicine Program at the Research Institute of The Hospital for Sick Children and a Professor in the Biochemistry Department at the University of Toronto. The major focus of her work has been to provide biological insights into how dynamic properties of proteins are related to function and methodological tools to enable better understanding of dynamic and disordered states. Her expertise is in using NMR and other biophysical and computational tools to study dynamic and disordered proteins and their interactions, including characterizing their dynamic complexes that are mediated by multivalent interactions. The ENSEMBLE program was developed by her lab to generate ensembles of conformers representing a disordered state. The Forman-Kay lab works on a number of projects of specific relevance to cancer and neurobiology. Most recently her lab has started to probe the role phase separation of disordered proteins in RNA processing bodies, a key regulatory process for neurological function. Her group also has a strong interest in CFTR, the cystic fibrosis transmembrane conductance regulator, particularly its cytoplasmic domains including the disordered regulatory R region.

Lab Information

University of Toronto

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Disordered Proteins 0 Bioinformatics 0 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (1)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Dawson JE, Bah A, Zhang Z, Vernon RM, Lin H, Chong PA, Vanama M, Sonenberg N, Gradinaru CC, and Forman-Kay JD. Non-cooperative 4E-BP2 folding with exchange between eIF4E-binding and binding-incompatible states tunes cap-dependent translation inhibition. Nat Commun, 2020 Jun 19. PMID: 32561718

  2. Gonatopoulos-Pournatzis T, Niibori R, Salter EW, Weatheritt RJ, Tsang B, Farhangmehr S, Liang X, Braunschweig U, Roth J, Zhang S, Henderson T, Sharma E, Quesnel-Vallières M, Permanyer J, Maier S, Georgiou J, Irimia M, Sonenberg N, Forman-Kay JD, Gingras AC, Collingridge GL, Woodin MA, Cordes SP, and Blencowe BJ. Autism-Misregulated eIF4G Microexons Control Synaptic Translation and Higher Order Cognitive Functions. Mol. Cell, 2020 03 19. PMID: 31999954

  3. Chong PA, and Forman-Kay JD. Oxidative Inhibition of Pbp1 Phase Separation. Biochemistry, 2019 07 16. PMID: 31282150

  4. Yang YM, Arsenault J, Bah A, Krzeminski M, Fekete A, Chao OY, Pacey LK, Wang A, Forman-Kay J, Hampson DR, and Wang LY. Identification of a molecular locus for normalizing dysregulated GABA release from interneurons in the Fragile X brain. Mol. Psychiatry, 2018 09 17. PMID: 30224722 [Epub ahead of print]

  5. Forman-Kay JD, Kriwacki RW, and Seydoux G. Phase Separation in Biology and Disease. J. Mol. Biol., 2018 11 02. PMID: 30213727

  6. Vernon RM, Chong PA, Tsang B, Kim TH, Bah A, Farber P, Lin H, and Forman-Kay JD. Pi-Pi contacts are an overlooked protein feature relevant to phase separation. Elife, 2018 02 09. PMID: 29424691

  7. Callebaut I, Chong PA, and Forman-Kay JD. CFTR structure. J. Cyst. Fibros., 2018 03 . PMID: 28866450


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2025 MolecularCloud